Movatterモバイル変換


[0]ホーム

URL:


DK2488554T3 - ANTIBODIES AGAINST EPHA3 - Google Patents

ANTIBODIES AGAINST EPHA3
Download PDF

Info

Publication number
DK2488554T3
DK2488554T3DK10777137.0TDK10777137TDK2488554T3DK 2488554 T3DK2488554 T3DK 2488554T3DK 10777137 TDK10777137 TDK 10777137TDK 2488554 T3DK2488554 T3DK 2488554T3
Authority
DK
Denmark
Prior art keywords
antibodies against
epha3
against epha3
antibodies
Prior art date
Application number
DK10777137.0T
Other languages
Danish (da)
Inventor
Kenneth Luehrsen
David Martinez
Christina Yi
Christopher R Bebbington
Geoffrey T Yarranton
Original Assignee
Humanigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humanigen IncfiledCriticalHumanigen Inc
Application grantedgrantedCritical
Publication of DK2488554T3publicationCriticalpatent/DK2488554T3/en

Links

Classifications

Landscapes

DK10777137.0T2009-10-142010-10-14 ANTIBODIES AGAINST EPHA3DK2488554T3 (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US25166809P2009-10-142009-10-14
PCT/US2010/052725WO2011053465A1 (en)2009-10-142010-10-14Antibodies to epha3

Publications (1)

Publication NumberPublication Date
DK2488554T3true DK2488554T3 (en)2019-09-02

Family

ID=43499991

Family Applications (1)

Application NumberTitlePriority DateFiling Date
DK10777137.0TDK2488554T3 (en)2009-10-142010-10-14 ANTIBODIES AGAINST EPHA3

Country Status (11)

CountryLink
US (2)US8664365B2 (en)
EP (1)EP2488554B1 (en)
JP (2)JP2013508292A (en)
CN (1)CN102666589B (en)
AU (1)AU2010313621C1 (en)
CA (1)CA2777068C (en)
DK (1)DK2488554T3 (en)
ES (1)ES2743558T3 (en)
PL (1)PL2488554T3 (en)
PT (1)PT2488554T (en)
WO (1)WO2011053465A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20110243934A1 (en)*2010-04-012011-10-06Kalobios Pharmaceuticals Inc.Epha3 antibodies for the treatment of multiple myeloma
CA2802723A1 (en)*2010-06-182011-12-22Kalobios Pharmaceuticals, Inc.Detection of epha3 as a marker of the presence of a solid tumor
US9109032B2 (en)2011-08-122015-08-18Kalobios Pharmaceuticals, Inc.Methods of treating hematological proliferative disorders by targeting EphA3 expressed on aberrant vasculature in bone marrow
PT3708583T (en)*2013-08-012022-05-13Five Prime Therapeutics IncAfucosylated anti-fgfr2iiib antibodies
KR20250034528A (en)2015-11-232025-03-11파이브 프라임 테라퓨틱스, 인크.Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
EP3512883A1 (en)2016-09-132019-07-24Humanigen, Inc.Epha3 antibodies for the treatment of pulmonary fibrosis
SG10202112636SA (en)2017-05-162021-12-30Five Prime Therapeutics IncAnti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
EP3758751A4 (en)*2018-02-282021-11-17Wuxi Biologics Ireland Limited.Monoclonal antibody against human lag-3, method for preparing same, and use thereof
CN114787190A (en)*2019-10-092022-07-22昆士兰医学研究所理事会 Targeting EPHA3 and its uses
US20220395532A1 (en)2019-11-082022-12-15Humanigen, Inc.Epha3 directed car-t cells for treatment of tumors
US20240025971A1 (en)*2020-10-232024-01-25Atreca, Inc.Antibodies to coronavirus sars-cov-2
CN118055945A (en)*2021-08-062024-05-17韩国生命工学研究院Novel anti-EPHA 2 chimeric antigen receptor and immune cells expressing same

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4816567A (en)1983-04-081989-03-28Genentech, Inc.Recombinant immunoglobin preparations
DE3883899T3 (en)1987-03-181999-04-22Sb2, Inc., Danville, Calif. CHANGED ANTIBODIES.
US5677425A (en)1987-09-041997-10-14Celltech Therapeutics LimitedRecombinant antibody
CA2111006C (en)1991-06-212008-04-08Andrew D. BoydA novel receptor-type tyrosine kinase and use thereof
US5714350A (en)1992-03-091998-02-03Protein Design Labs, Inc.Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
CA2118508A1 (en)1992-04-241993-11-11Elizabeth S. WardRecombinant production of immunoglobulin-like domains in prokaryotic cells
NO175798C (en)1992-07-221994-12-07Sinvent As Method and device for active noise cancellation in a local area
US5885573A (en)1993-06-011999-03-23Arch Development CorporationMethods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6121022A (en)1995-04-142000-09-19Genentech, Inc.Altered polypeptides with increased half-life
US5869046A (en)1995-04-141999-02-09Genentech, Inc.Altered polypeptides with increased half-life
US6277375B1 (en)1997-03-032001-08-21Board Of Regents, The University Of Texas SystemImmunoglobulin-like domains with increased half-lives
US6194551B1 (en)1998-04-022001-02-27Genentech, Inc.Polypeptide variants
ATE458007T1 (en)1998-04-202010-03-15Glycart Biotechnology Ag GLYCOSYLATION ENGINEERING OF ANTIBODIES TO IMPROVE ANTIBODIES-DEPENDENT CELL-MEDIATED CYTOTOXICITY
GB9809951D0 (en)1998-05-081998-07-08Univ Cambridge TechBinding molecules
PL220113B1 (en)1999-01-152015-08-31Genentech IncVariant of parent polypeptide comprising the Fc region, polypeptide comprising a variant of the Fc region with altered binding affinity of Fc gamma receptor (FcγR), a polypeptide comprising the variant of Fc region with altered binding affinity of neonatal Fc receptor (FcRn), a composition, isolated nucleic acid, vector, host cell, method for preparing the polypeptide variant, the use of the polypeptide variant and method for preparing a the Fc region variant
US6737056B1 (en)1999-01-152004-05-18Genentech, Inc.Polypeptide variants with altered effector function
EP2275541B1 (en)1999-04-092016-03-23Kyowa Hakko Kirin Co., Ltd.Method for controlling the activity of immunologically functional molecule
DE60139720D1 (en)2000-06-282009-10-08Glycofi Inc Process for the preparation of modified glycoproteins
US6946292B2 (en)2000-10-062005-09-20Kyowa Hakko Kogyo Co., Ltd.Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP3569610A3 (en)2000-12-122020-03-18Medlmmune, LLCMolecules with extended half lives, compositions and uses thereof
US7317091B2 (en)2002-03-012008-01-08Xencor, Inc.Optimized Fc variants
CA2478297C (en)2002-03-192013-05-14Plant Research International B.V.Optimizing glycan processing in plants
KR100980065B1 (en)2002-09-272010-09-03젠코어 인코포레이티드Optimized fc variants and methods for their generation
WO2005069970A2 (en)*2004-01-202005-08-04Kalobios, Inc.Antibody specificity transfer using minimal essential binding determinants
US7659374B2 (en)2004-08-162010-02-09Medimmune, LlcEph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
US8222253B2 (en)*2004-10-232012-07-17Case Western Reserve UniversityPeptide and small molecule agonists of EphA and their uses
PL3540062T3 (en)2004-11-162021-12-27Humanigen, Inc.Immunoglobulin variable region cassette exchange
US8211648B2 (en)2005-07-222012-07-03Kalobios Pharmaceuticals, Inc.Secretion of antibodies without signal peptides from bacteria
US7846724B2 (en)2006-04-112010-12-07Hoffmann-La Roche Inc.Method for selecting CHO cell for production of glycosylated antibodies
WO2008060092A1 (en)2006-11-172008-05-22Sang Yun ParkRotative force generator
ES2910298T3 (en)*2007-03-082022-05-12Humanigen Inc Antibodies against EphA3 for the treatment of solid tumors
CL2008002782A1 (en)2007-09-212009-07-31Genentech Inc Neutralizing anti-bv8 antibody; composition comprising it; and its use to treat tumors in humans previously treated with a vascular endothelial growth factor antagonist.
US8834870B2 (en)*2009-03-062014-09-16Kalobios Pharmaceuticals, Inc.Treatment of leukemias and chronic myeloproliferative diseases with antibodies to EphA3

Also Published As

Publication numberPublication date
CN102666589A (en)2012-09-12
JP2016094424A (en)2016-05-26
EP2488554B1 (en)2019-07-24
AU2010313621A1 (en)2012-05-03
CA2777068C (en)2020-05-26
US9290571B2 (en)2016-03-22
AU2010313621B2 (en)2015-07-30
US20140120114A1 (en)2014-05-01
ES2743558T3 (en)2020-02-19
US8664365B2 (en)2014-03-04
WO2011053465A1 (en)2011-05-05
AU2010313621C1 (en)2015-11-26
PL2488554T3 (en)2020-03-31
US20110123549A1 (en)2011-05-26
PT2488554T (en)2019-09-13
CA2777068A1 (en)2011-05-05
JP2013508292A (en)2013-03-07
EP2488554A1 (en)2012-08-22
CN102666589B (en)2014-08-20

Similar Documents

PublicationPublication DateTitle
BRPI0917148A2 (en) anti-cd5 antibodies
ATE554604T1 (en) IMPROVED EARBUDS
BRPI0906877A2 (en) Improved anti-trkb antibodies
DK2488554T3 (en) ANTIBODIES AGAINST EPHA3
DK2338287T3 (en) transducer
BRPI0919800A2 (en) packing
BRPI0920653A2 (en) packing
EP2337798A4 (en) BSA-SPECIFIC ANTIBODIES
DK2330131T3 (en) Antibodies against HER2-truncated variant CTF-611
EP2350385A4 (en) FORM FIELD
BRPI0909633A2 (en) anti-tyrp1 antibodies
BRPI0915562A2 (en) tamis improved
BRPI0906828A2 (en) Packing
BRPI0915442A2 (en) tamis improved
BRPI0912769A2 (en) anti-pirb antibodies
FR2931351B1 (en) VACUUM
FI20070943L (en) Packaging
DE602008006342D1 (en) packaging
FI20085942A0 (en) Well
ATE530412T1 (en) PACKAGING
DE602008002548D1 (en) packaging arrangement
DE112008003789A5 (en) vibration
ES1067844Y (en) IMPROVED BURLET
EP2277426A4 (en) VACUUM
UA18789S (en) PACKAGING

[8]ページ先頭

©2009-2025 Movatter.jp